Could a Cure for Alzheimer’s be Invented in the Triangle? Absolutely.

Old people with neurodegenerative diseases
By The Editors of Talking Trials,

Currently, the estimated annual cost of nine common neurological diseases totals to $800 billion, predictably increasing as the elderly population doubles by 2050. More specifically, there is a catastrophic unmet need in Alzheimer’s disease treatment, prevention and clinical research. In a recent segment with WRAL News’ Health Team with Dr. Allen Mask, Worldwide Clinical Trials’ chief operating officer, Peter Benton, discusses Worldwide’s uncommon approach to fighting against neurodegenerative diseases through its recent partnership with Datavant.

Read More

Q&A with Natalia Drosopoulou: Important Implications of NIA-AA Framework for Alzheimer’s Disease Research – Part 3 of 3

National Institute of Aging and Alzheimer’s Association Framework for Alzheimer’s Disease Research
By Editors of Talking Trials,

In a major departure, the new Alzheimer’s disease (AD) research framework by the National Institutes on Aging and Alzheimer’s Association (NIA-AA) separates clinical symptoms from pathological state (1). This shift in thinking away from AD as a clinical-pathological construct and then as a clinical-biomarker construct (where biomarkers were used to support an AD diagnosis) represents the key feature to the updated research framework released in 2017 (2). 

Read More

Q&A with Natalia Drosopoulou: Important Implications of NIA-AA Framework for Alzheimer’s Disease Research – Part 2 of 3

National Institute of Aging and Alzheimer’s Association Framework for Alzheimer’s Disease Research
By Editors of Talking Trials,

  The common Alzheimer’s disease research framework proposed in 2017 by the National Institute on Aging and Alzheimer’s Association (NIA-AA) pivots upon the understanding and acknowledgment that Alzheimer’s disease (AD) refers to an aggregate of pathophysiologic processes and therefore can be uniquely defined in vivo by biomarkers and, of course, by post mortem pathologic changes but conspicuously not by clinical symptomatology (1, 2).

Read More

Q&A with Natalia Drosopoulou: Important Implications of NIA-AA Framework for Alzheimer’s Disease Research – Part 1 of 3

National Institute of Aging and Alzheimer’s Association Framework for Alzheimer’s Disease Research
By Editors of Talking Trials,

  In 2017, the National Institute of Aging and Alzheimer’s Association (NIA-AA) proposed a common research framework to help clinical investigators establish a research agenda and evaluate the impact of various therapeutics in the Alzheimer’s disease (AD) continuum, and specifically to define and stage AD and facilitate research reporting. 

Read More

How eCOA Simplifies Alzheimer’s Disease Research

Alzheimer’s disease research, electronic Clinical Outcomes Assessments

  Alzheimer’s disease research is taking advantage of new technology, including eCOA. To understand this trend, Talking Trials spoke with Will Tucker, Worldwide Clinical Trials’ Associate Director of Clinical Assessment Technologies (CAT). Will serves as a key leader in the CAT department, managing a highly experienced scale management, rater training, and reliability group that is seamlessly integrated with Worldwide’s Site Feasibility & Recruitment, Project Management, Clinical Operations, and Medical Monitoring groups. As the pharmaceutical industry moves away from paper administration of scales and toward electronic solutions, CAT now partners with industry leaders in electronic Clinical Outcomes Assessments (eCOA) and has expanded its offerings to include eCOA vendor oversight.

Read More